Health Discovery Corporation Applauds American Cancer Society’s Decision Against The Use Of The PSA For Routine Prostate Cancer Screening
Health Discovery Corporation (OTCBB: HDVY) announced today that it supports the American Cancer Society’s decision to issue new guidelines in the face of substantial data found in the largest prostate cancer studies ever conducted that were recently published in the New England Journal of Medicine in 2009. These published studies warned that using PSA to screen for prostate cancer doesn't necessarily save lives, and noted any benefits can come at a high price including over-diagnosis of prostate cancer leading to unnecessary treatments which can result in impotence and incontinence which are potentially devastating and life changing side effects in these men.
Health Discovery Corporation’s Science Advisory Board member, Dr. Thomas Stamey, the founder and former chairman of the Department of Urology at Stanford University Medical Center, and a world renowned leader in prostate cancer published in the Journal of Urology several years ago: “The era of the PSA is over.” At the time of Dr. Stamey's landmark publication, Health Discovery Corporation began the development of its new gene-based molecular diagnostic test for prostate cancer.
“Health Discovery Corporation’s new, urine-based 4-gene prostate cancer test which has been shown to have a 90% Sensitivity (for finding clinically significant, grade 3 or higher prostate cancer cells) and a 97% Specificity (for finding non-cancerous cells) was recently published in the peer-reviewed publication UroToday International,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We are very pleased that the American Cancer Society is now warning men and their doctors about the risks of using the PSA test for routine prostate cancer screening," said Dr. Barnhill.
Health Discovery Corporation's new urine-based 4-gene prostate cancer test is licensed on a royalty based, worldwide co-exclusive basis to Quest Diagnostics Incorporated (NYSE: DGX) and Abbott (NYSE: ABT).The Associate Press released a story today on the American Cancer Society’s new guidelines titled, “Cancer society stops urging docs to offer PSA test,” by Mike Stobbe, AP Medical Writer, and Stephanie Nano contributed to the story.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV